Organization | University of Florence

University of Florence Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Florence Italy (1321)

Organization Overview

First Clinical Trial

1991

NCT00003063

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

A. Meyer University Childrens' Hospital | AO Careggi | AOU Careggi | AOU- Careggi | AOU Careggi - University of Florence, Florence, Italy | ASL 10 Florence Italy | ASL 10 Florence, Italy | Azienda Ospedaliera Careggi | Azienda Ospedaliera Universitaria Careggi | Azienda Ospedaliero-Universitaria A. Meyer, Firenze, Italy | Azienda Ospedaliero-Universitaria Careggi | Azienda Ospedaliero-Universitaria Careggi University of Florence | Azienda Ospedaliero, Universitaria Meyer | Azienda Sanitaria di Firenze | Aziendo Osperdaliero Universitaria Careggi Oncologia | Careggi Hospital | Careggi Hospital, division of Invasive Cardiology | Careggi Hospital, Division of Invasive Cardiology | Careggi Hospital , Florence, Italy | Careggi Hospital, Florence, Italy | Careggi University Hospital | Children's Hospital A. Meyer of Firenze, Italy | Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Italy | Division of Cardiology, Careggi Hospital, Florence, Italy | Division of Invasive Cardiology, Careggi Hospital | Institute of Neuroscience, Florence, Italy | IRCCS Centro San Giovanni di Dio Fatebenefratelli | Ospedale Careggi, Firenze - Italy | Ospedale Careggi, Florence, Italy | Ospedale di Careggi BMT Unit Department of Haematology | Ospedale Meyer | Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy | Servizio di Gastroenterologia dell'Azienda Ospdedaliero - Universitaria Anna Meyer di Firenze | Universita Degli Studi di Florence | Universita Degli Studi di Florence - Policlinico di Careggi | Universitaria Anna Meyer di Firenze | University of Florence | University of Florence- AOU Careggi | University of Florence, Florence, Italy | University of Florence, Italy | U.O di Ematologia, AO of Careggi, viale Morgagni n.85-50134-Firenze

Active Ingredients

Drugs in Phase 4 Trials (30)

acetylsalicylic acid (aspirin) (2 trials)

atropine (1 trial)

bisacodyl (Halflytely) (1 trial)

bivalirudin (angiomax) (1 trial)

clopidogrel (plavix) (2 trials)

dalteparin (fragmin) (1 trial)

estradiol (progynon depot) (1 trial)

fentanyl (Innovar) (1 trial)

heparin (liquaemin) (2 trials)

hpv 16/18 vaccine (Cervarix) (1 trial)

human fibrin (Tisseel) (1 trial)

hypromelloses (1 trial)

neostigmine (bloxiverz) (1 trial)

ondansetron (zofran) (2 trials)

ozonated oil (1 trial)

palmitoylethanolamide (1 trial)

polyethylene glycol (1 trial)

prasugrel (effient) (3 trials)

progestin (1 trial)

propofol (diprivan) (1 trial)

rocuronium (zemuron) (1 trial)

sargramostim (leukine) (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (2 trials)

sugammadex (bridion) (1 trial)

tadalafil (cialis) (1 trial)

testosterone (delatestryl) (1 trial)

ticagrelor (brilinta) (3 trials)

vardenafil (levitra) (1 trial)

vitamin c (1 trial)

Drugs in Phase 3 Trials (30)

anastrozole (arimidex) (1 trial)

bisoprolol (zebeta) (1 trial)

bone marrow derived mononuclear cells (1 trial)

carlecortemcel-l (1 trial)

cd14+cd34+cells (1 trial)

cisplatin (platinol) (1 trial)

cyclosporine (sandimmune) (1 trial)

dolutegravir (tivicay) (1 trial)

etoposide (vepesid) (1 trial)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (1 trial)

follitropin alfa (Gonal-F) (1 trial)

gemcitabine (gemzar) (1 trial)

ibuprofen (motrin) (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

ketamine (ketalar) (1 trial)

lactobacillus reuteri (1 trial)

lamivudine (epivir) (1 trial)

letrozole (femara) (1 trial)

leucovorin (1 trial)

levamisole (ergamisol) (1 trial)

propranolol (inderal) (4 trials)

ramipril (altace) (1 trial)

ribavirin (virazole) (1 trial)

sacubitril (Entresto) (2 trials)

stem cells (1 trial)

tamoxifen (nolvadex) (1 trial)

thalidomide (Thalomid) (1 trial)

valsartan (diovan) (2 trials)

Drugs in Phase 2 Trials (20)

azacitidine (vidaza) (1 trial)

azithromycin (zithromax) (1 trial)

cetuximab (erbitux) (1 trial)

choline alphoscerate (1 trial)

decitabine (dacogen) (1 trial)

doxycycline (vibramycin) (1 trial)

durvalumab (imfinzi) (1 trial)

everolimus (zortress) (1 trial)

forodesine (1 trial)

glucose (1 trial)

ibandronate (boniva) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

nepadutant (1 trial)

oxytocin (syntocinon) (1 trial)

paclitaxel (taxol) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

sertraline (zoloft) (1 trial)

topiramate (topamax) (1 trial)

xanthophyll (1 trial)

Drugs in Phase 1 Trials (1)

lactobacillus delbrueckii (1 trial)

Drugs in Other Trials (10)

abiraterone (zytiga) (1 trial)

alteplase (Activase) (1 trial)

anagrelide (agrylin) (1 trial)

caffeine (1 trial)

citrus extract (1 trial)

human fecal microbiota (Reybota) (1 trial)

poractant alfa (curosurf) (1 trial)

sodium butyrate (1 trial)

vitamin e (1 trial)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Habitual (Phase 4)

Abortion, Spontaneous (Phase 4)

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 3)

Brain Diseases (Phase 2)

Brain Ischemia (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Hypertrophic (Phase 3)

Cardiotoxicity (Phase 3)

Cataract (Phase 4)

Cognitive Dysfunction (Phase 2)

Colic (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Colorectal Neoplasms (Phase 3)

Compulsive Personality Disorder (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Crohn Disease (Phase 3)

Delayed Emergence from Anesthesia (Phase 4)

Disease (Phase 4)

Diverticular Diseases (Phase 3)

Diverticulitis (Phase 3)

Diverticulum (Phase 3)

Ductus Arteriosus, Patent (Phase 3)

Erectile Dysfunction (Phase 4)

Extravasation of Diagnostic and Therapeutic Materials (Phase 4)

Eye Infections (Phase 4)

Fibrosis (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hematoma (Phase 4)

Hepatitis, Chronic (Phase 3)

Hodgkin Disease (Phase 3)

Hyperplasia (Phase 4)

Hypertrophy (Phase 3)

Hypogonadism (Phase 4)

Hypothermia (Phase 2)

Hypoxia (Phase 2)

Hypoxia-Ischemia, Brain (Phase 2)

Infant, Newborn, Diseases (Phase 2)

Infarction (Phase 4)

Infertility (Phase 3)

Infertility, Male (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Ischemia (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lower Urinary Tract Symptoms (Phase 4)

Lymphohistiocytosis, Hemophagocytic (Phase 3)

Lymphoma (Phase 2)

Melanoma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Neoplasms (Phase 3)

Obsessive-Compulsive Disorder (Phase 4)

Pancreatic Neoplasms (Phase 3)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Phlebitis (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Premature Birth (Phase 3)

Prostatic Hyperplasia (Phase 4)

Retinal Diseases (Phase 3)

Retinopathy of Prematurity (Phase 3)

Schizophrenia (Phase 2)

Status Epilepticus (Phase 3)

ST Elevation Myocardial Infarction (Phase 4)

Ulcer (Phase 3)

Uterine Cervical Neoplasms (Phase 4)

Ventricular Remodeling (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 68
# of Trial APIs: 91